BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study Transcript
Source: SeekingAlpha
2026-01-09 11:25:07 ET
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study January 9, 2026 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study Transcript
BridgeBio Pharma Inc.
NASDAQ: BBIO
BBIO Trading
-4.84% G/L:
$68.97 Last:
696,555 Volume:
$70.35 Open:
BBIO Latest News
BBIO Stock Data
$13,905,867,946
157,635,809
2.34%
155
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
